scholarly journals PO-298 Pegylated recombinant human hyaluronidase PH20 (PEGPH20) increases tumour uptake and efficacy of cetuximab in a human pancreatic cancer xenograft model

Author(s):  
J Souratha ◽  
R Osgood ◽  
J Cowell ◽  
A Fathallah ◽  
C Thompson ◽  
...  
2010 ◽  
Vol 64 (5) ◽  
pp. 309-312 ◽  
Author(s):  
Rong-sheng Wang ◽  
Ling-xiang Liu ◽  
Yan-hong Gu ◽  
Qing-feng Lin ◽  
Ren-hua Guo ◽  
...  

2009 ◽  
Vol 63 (5) ◽  
pp. 325
Author(s):  
Wang Rong-sheng ◽  
Liu Ling-xiang ◽  
Lin Qing-feng ◽  
Guo Ren-hua ◽  
SHU Yong-qian

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2331 ◽  
Author(s):  
JebaMercy Gnanasekaran ◽  
Adi Binder Gallimidi ◽  
Elias Saba ◽  
Karthikeyan Pandi ◽  
Luba Eli Berchoer ◽  
...  

Porphyromonas gingivalis is a member of the dysbiotic oral microbiome associated with oral inflammation and periodontal disease. Intriguingly, epidemiological studies link P. gingivalis to an increased risk of pancreatic cancer. Given that oral bacteria are detected in human pancreatic cancer, and both mouse and human pancreata harbor microbiota, we explored the involvement of P. gingivalis in pancreatic tumorigenesis using cell lines and a xenograft model. Live P. gingivalis induced proliferation of pancreatic cancer cells; however, surprisingly, this effect was independent of Toll-like receptor 2, the innate immune receptor that is engaged in response to P. gingivalis on other cancer and immune cells, and is required for P. gingivalis to induce alveolar bone resorption. Instead, we found that P. gingivalis survives inside pancreatic cancer cells, a trait that can be enhanced in vitro and is increased by hypoxia, a central characteristic of pancreatic cancer. Increased tumor cell proliferation was related to the degree of intracellular persistence, and infection of tumor cells with P. gingivalis led to enhanced growth in vivo. To the best of our knowledge, this study is the first to demonstrate the direct effect of exposure to P. gingivalis on the tumorigenic behavior of pancreatic cancer cell lines. Our findings shed light on potential mechanisms underlying the pancreatic cancer–periodontitis link.


Pancreas ◽  
2006 ◽  
Vol 33 (2) ◽  
pp. 142-147 ◽  
Author(s):  
Masanori Tsujie ◽  
Shoji Nakamori ◽  
Shin Nakahira ◽  
Setsuo Takeda ◽  
Yuji Takahashi ◽  
...  

Surgery ◽  
2012 ◽  
Vol 152 (3) ◽  
pp. 441-448 ◽  
Author(s):  
Quyen D. Chu ◽  
Guang Sun ◽  
Matt Pope ◽  
Natalia Luraguiz ◽  
David T. Curiel ◽  
...  

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 198-198
Author(s):  
M. D. Girgis ◽  
K. McCabe ◽  
T. Olafsen ◽  
F. Bergara ◽  
V. Kenanova ◽  
...  

198 Background: Antibody-based therapeutics is a rapidly growing field. Small engineered antibody fragments, such as the cys-diabody demonstrate similar antigen affinity compared to the parental antibody but have a shorter serum half-life (4hrs) and possess the ability to be conjugated to nanoparticles. Our goal was to engineer an anti-CA19-9 cys-diabody fragment in hopes of imaging and targeting pancreatic cancer. Methods: The anti-CA19-9 cys-diabody was created by cloning the variable region of the parental antibody, engineering a C-terminus cysteine, expressing in NS0 cells followed by protein purification utilizing HPLC. Maleimide chemistry was used to conjugate the cys-diabody to PLNs through the engineered cysteine residues. Immunofluorescence and flow cytometry were used to evaluate targeting of cys-diabody and diabody conjugated PLNs to human pancreatic cancer cell lines. The cys-diabody was evaluated in a mouse xenograft model harboring CA19-9 positive (BxPC3) and negative (MiaPaca) tumors. The cys-diabody was radiolabeled with a positron emitter (I-124) and microPET/CT were performed after tail vein injection. Percent of injected dose per gram (%ID/g) of radioactivity was measured in blood and tumor to provide objective confirmation of the microPET images. Results: Immunofluorescence and flow cytometry showed specific binding of the anti-CA19-9 cys- diabody. Tumor xenograft imaging of the anti-CA19-9 cys-diabody demonstrated an average tumor:blood (%ID/g) ratio of 3.3 and positive:negative tumor ratio of 7.4. Successful conjugation of the cys-diabody to PLNs was indicated by immunofluorescence showing specific targeting of PLN-cys- diabody conjugate to human pancreatic cancer cells in vitro. Conclusions: Our results show that the anti-CA19.9 cys- diabody targets pancreatic cancer providing specific molecular imaging in tumor xenograft models. Furthermore, the PLN-cys-diabody conjugate targets human pancreatic cancer cells with the potential to deliver targeted treatment. Further studies evaluating the in vivo ability of the PLN-cys-diabody conjugate to target pancreatic cancer need to be performed. No significant financial relationships to disclose.


PLoS ONE ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. e20330 ◽  
Author(s):  
Amanda Shanks Huynh ◽  
Dominique F. Abrahams ◽  
Monica S. Torres ◽  
Margaret K. Baldwin ◽  
Robert J. Gillies ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document